Clinical and Post-Market

Demonstrate complete regulatory compliance by ensuring your in vitro diagnostic (IVD) device conforms to all applicable global requirements.

Delivering compliant IVD products to global markets

Choose Apotech for clinical compliance you can trust

Before placing an IVD device on the market, manufacturers must demonstrate compliance with all applicable global regulatory requirements  including In Vitro Diagnostic Regulation (IVDR), 21 CFR and the UK MDR 2002. 

At Apotech, our experienced team can make sure that you are conforming with the appropriate conformity assessment procedures. Working on your behalf, we can help you demonstrate that your IVD device achieves its intended purpose and corresponds to its claimed performance throughout its lifetime.

Smiling group of diverse businesspeople going over paperwork together and working on a laptop at a table in an office

Trusted by top-tier teams worldwide

Performance Evaluation Plan (PEP)

The PEP provides you with the opportunity to combine the design inputs for performance and safety with your risk management outputs to align them with the IVDR requirements described in Annex I. 

Our team at Apotech can collaborate with you to craft a structured PEP, aligning with factors like your IVD's risk class, its intended use and various technological specifications to ensure complete compliance with the more stringent IVDR. We can also support you with:

  • Device classification
  • The intended purpose and characteristics of your device
  • Identification of analyte or marker 
  • Intended use, user and indications for use
  • General Safety and Performance Requirements (GSPR) 
  • Analytical methods and clinical performance
  • Development, validity, analytical and clinical performance
  • State-of-the-art status
  • Benefit-risk
  • PMPF plan

Performance Evaluation Report (PER)

Your PER is the key document for performance evaluation, bringing all elements of clinical evidence together for the device in context with benefit-risk statements and state-of-the-art status. 

It provides you with an opportunity to discuss your IVD device in terms of its intended purpose and risk classification. Therefore, manufacturers should compile evidence, determine the benefit-risk and document the performance evaluation and its output as part of this report. 

However, many IVD manufacturers face challenges in producing the clinical data necessary under the IVDR due to significantly more stringent requirements. 

That’s why at Apotech, we can offer end-to-end support in the following areas:

  • Clinical evidence justification
  • Literature search methodology, protocol and report
  • Device description, intended use, performance and safety claims
  • Scientific validity, analytical performance and clinical performance
  • Clinical evidence and state-of-the-art comparison
  • PMPF evaluation report updates

Post-Market Surveillance (PMS) and Post-Market Performance Follow up (PMPF) 

The IVDR sets out that ‘the clinical evidence and its assessment in the performance evaluation report shall be updated throughout the life cycle of the device.’ So, to fulfil post-market requirements, you’ll need to conduct a Post-market Performance Follow-up (PMPF). 

The PMPF is meant to be a continuous collection of clinical data on the performance of your device after it has been placed on the market. 

Post-market information, such as data from the manufacturer’s post-market surveillance system should be reviewed regularly and used to determine the potential impact on the risks, clinical benefit and whether there is a need to update the performance evaluation report of the IVD. 

As a manufacturer, you must ensure that all appropriate methods, procedures and product-specific triggers to proactively collect and evaluate safety, performance and scientific data are included as part of your PMPF plan.

Our team can support you with:

  • Developing comprehensive PMPF strategies and plans
  • Identifying relevant data sources, establishing data collection protocols and implementing systems for timely data analysis and reporting
  • Updating PEP or PER as part of the PMPF
  • Updating IVD clinical evidence, as appropriate
  • Post-market performance studies
  • Establishing procedures for signal detection, investigation and risk management, including the implementation of corrective and preventive actions (CAPAs) as necessary


Manufacturers in the USA are expected to compile and maintain documentation that demonstrates the analytical and clinical performance of their IVD devices. From analytical validation studies to regulatory submissions and post-market surveillance, navigating the clinical aspects of IVD development requires meticulous planning, execution and adherence to regulatory requirements. 

Our team can support you in the following clinical areas.

  • Analytical and clinical performance evaluation: The FDA expects manufacturers to demonstrate both the analytical and clinical performance of their IVD devices. This involves conducting studies to assess the accuracy, precision, sensitivity, specificity and various other performance-related characteristics of the device.
  • Analytical validation studies: Manufacturers must conduct analytical validation studies to evaluate your device's performance under controlled laboratory conditions. These studies assess its ability to accurately and reliably measure analytes of interest.
  • Clinical validation studies: Clinical validation studies are conducted to evaluate the device's performance in real-world clinical settings. These studies compare the device's results to those of a reference method or gold standard and assess its diagnostic accuracy, sensitivity, specificity and various other clinical performance characteristics.
  • Post-market surveillance (PMS): Manufacturers must implement post-market surveillance programmes to monitor the performance of their IVD devices after they are placed on the market. This includes not only collecting and analysing data on device failures, adverse events and several other safety or performance issues but also taking appropriate corrective and preventive actions when required.

Clinical trial consulting

Conducted by a team of experts with more than two decades of experience in clinical trials and compliance, we can provide tailored IVD clinical study design and protocol development services that carefully balance the needs of your stakeholders. 

Designed to assess the analytical and clinical performance of IVD technologies, clinical trials provide critical evidence to support the diagnostic accuracy, reliability and relevance of your IVD devices in real-world healthcare settings. 

Our clinical trial research consultants can provide expert guidance on essential elements of study design, considering the necessity, implications and practicality of each decision. 

We can also support you with:  

  • Study design
  • Health economics and reimbursement planning
  • Literature review
  • Protocol writing and review
  • Resource planning
  • Statistical analysis plans for clinical trial protocols
  • Clinical investigation plan
  • Investigators brochure
Excited to work together on your next project?

Why choose Apotech for IVD clinical and post-market services?

Article 56 (1) of the IVDR states that IVD manufacturers must specify and justify the level of clinical evidence given a device’s characteristics and its intended purpose. Therefore, defining this intended purpose must be considered a key driver behind its overall assessment. 

Manufacturers must also ensure that they meet the essential requirements of the Medical Devices Regulations 2002 using data gathered through a performance evaluation. 

At Apotech, we can support you during the clinical stages of your IVD development in the following areas: 

  • Data establishment
  • Performance Evaluation Plan (PEP)
  • Performance Evaluation Report (PER)
  • Post-Market Performance Follow-Up (PMPF)
  • Validity
  • Analytical performance
  • Clinical performance

FAQs on IVD clinical and post-market services

At Apotech, we provide a tailored approach to our IVD clinical and post-market services. We aim to make the process as simple to understand as possible and are always on hand to answer any questions you might have. 

Here are some of the questions we get asked most often.

Featured case studies

​GCP Audits – Europe

Seagen is a global biotechnology company dedicated to revolutionizing cancer care. They are Headquartered in the US & Switzerland with a large footprint in the EU.

Read More

Outsourced internal GMP & GVP Audits

Outsourced internal GMP & GVP Audits Introduction Multinational biotech The French affiliate of a multinational Biotech company has its own QMS. Upon the QP responsibility, they conduct their internal audit with a 3-year plan (at the end of a 3 year cycle, they have audited all of their processes). Apotech consultants  2 External auditors Both…

Read More

GVP Audits Worldwide

GVP Audits Worldwide Introduction US Biotechnology Our client is a global Biotechnology company dedicated to genetics and molecular biology. They are Headquartered in the US, with offices in most major economies. Apotech auditors  Our Auditors have 20+ years’ experience in the industry and have all conducted over 100 GVP audits. Types of Audits Affiliate Distributor/…

Read More

Ready to get started?